Articles tagged with: Bortezomib
News»
One of the issues that a physician may consider when deciding how to treat a myeloma patient is the impact different treatment options may have on the patient’s bones.
If a patient already has extensive bone damage resulting from multiple myeloma, a physician may lean more toward treatments that are believed to halt, or even counteract, the bone destruction the patient has been experiencing.
Previous research has shown that Velcade (bortezomib) may be able to help rebuild the bones of myeloma patients (see related Beacon news).
However, there is currently …
NewsFlash »
Results from a small retrospective analysis conducted in Japan indicate that injection site reactions from subcutaneous (under the skin) injections of Velcade (bortezomib) are more likely to occur during the first cycle of treatment than in later cycles.
A third of patients in the study developed injection site reactions – such as swelling, redness, or itchiness – during the first cycle of treatment. However, the share of patients experiencing such reactions dropped to one fifth during later cycles.
In the Japanese study, investigators retrospectively analyzed data from 20 multiple myeloma patients with a median age of 72 years who were newly diagnosed (60 percent) or had relapsed/refractory disease (40 percent).
Overall, 65 percent of patients developed injection site reactions at some point during their subcutaneous Velcade treatment.
The Japanese researchers found that the rate of injection site reactions was significantly higher during the first treatment cycle compared to subsequent cycles (34 percent versus 20 percent, respectively).
The rate of moderate or severe injection site reactions was also significantly higher during the first cycle compared to subsequent cycles (16 percent versus 1 percent, respectively).
Injections in the abdomen caused fewer moderate or severe injection site reactions (2 percent), compared to injections in the thigh (11 percent).
According to the researchers, the higher rates seen with injections to the thigh may be due to the fact that the thigh contains less fat tissue than the abdomen.
The researchers note that stage of disease and patient weight had no impact on the rate or severity of the injection site reactions.
Based on their findings, they recommend better management of injection site reactions, particularly among patients who receive injections in their thigh during their first treatment cycle.
They add that treatment with corticosteroids may prevent, or provide relief from, injection site reactions.
For more information, please refer to the study in the International Journal of Hematology (abstract).
News»
Results from three clinical trials involving the investigational drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.
The trials evaluated the efficacy of filanesib (ARRY-520) alone and in combination with other agents as potential treatments for relapsed and refractory multiple myeloma patients.
Overall, the trial results presented at ASH confirm existing impressions of filanesib as a promising potential myeloma therapy.
Results of a Phase 2 trial of filanesib with or without low-dose dexamethasone (Decadron) show that 16 percent of patients who …
News»
This Monday was the third day of the 2013 American Society of Hematology (ASH) annual meeting, which was held in New Orleans.
More than any other day of the conference, Monday was packed with important myeloma presentations, from 7:00 in the morning until almost 8:00 in the evening.
This ASH update will summarize the oral presentation sessions about treatment-related myeloma studies that were held Monday morning. An ASH update that was published on Wednesday focused on the sessions that were held Monday afternoon and evening.
Monday morning started with three simultaneous …
News»
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of the oral …
News»
Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this session was …
News»
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in the form …
